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Background: Flavonoids, polyphenolic compounds concentrated in fruits and vegetables, have experimentally demonstrated
chemopreventive effects against oesophageal and gastric cancer. Few epidemiologic studies have examined flavonoid intake and
incidence of these cancers, and none have considered survival.
Methods: In this USA multicentre population-based study, case participants (diagnosed during 1993–1995 with oesophageal
adenocarcinoma (OEA, n¼ 274), gastric cardia adenocarcinoma (GCA, n¼ 248), oesophageal squamous cell carcinoma
(OES, n¼ 191), and other gastric adenocarcinoma (OGA, n¼ 341)) and frequency-matched controls (n¼ 662) were interviewed.
Food frequency questionnaire responses were linked with USDA Flavonoid Databases and available literature for six flavonoid
classes and lignans. Case participants were followed until 2000 for vital status. Multivariable-adjusted odds ratios (ORs) and hazard
ratios (HRs) (95% confidence intervals (CIs)) were estimated, comparing highest with lowest intake quartiles, using polytomous
logistic and proportional hazards regressions, respectively.
Results: Little or no consistent association was found for total flavonoid intake (main population sources: black tea, orange/
grapefruit juice, and wine) and incidence or survival for any tumour type. Intake of anthocyanidins, common in wine and fruit juice,
was associated with a 57% reduction in the risk of incident OEA (OR¼ 0.43, 95% CI¼ 0.29–0.66) and OES (OR¼ 0.43, 95%
CI¼ 0.26–0.70). The ORs for isoflavones, for which coffee was the main source, were increased for all tumours, except
OES. Anthocyanidins were associated with decreased risk of mortality for GCA (HR¼ 0.63, 95% CI¼ 0.42–0.95) and modestly for
OEA (HR¼ 0.87, 95% CI¼ 0.60–1.26), but CIs were wide.
Conclusions: Our findings, if confirmed, suggest that increased dietary anthocyanidin intake may reduce incidence and improve
survival for these cancers.
Over the past two decades, oesophageal adenocarcinoma (OEA)
and gastric cardia adenocarcinoma (GCA) have been among the
most rapidly increasing cancer types in the United States and other
Western countries (Devesa et al, 1998; Simard et al, 2012).
Oesophageal adenocarcinoma and GCA are often considered as
one clinical entity because they are both epithelial cancers
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originating in or near the gastroesophageal junction and have
similar 5-year survival rates of B26% (Wijnhoven et al, 1999).
Still, oesophageal squamous cell carcinoma (OES) and other (non-
cardia) gastric adenocarcinoma (OGA) are the most common
forms of oesophageal and gastric cancer worldwide. In addition to
geographic variation, these four cancer types have differing risk
factors (Hongo et al, 2009; de Martel et al, 2013). Thus, considering
them as distinct entities will help to elucidate the underlying
aetiology.
Epidemiologic studies have shown that diets high in fruits and
vegetables are inversely associated with oesophageal and gastric
cancer incidence (Lunet et al, 2007; Li et al, 2014). Flavonoids,
which are a group of bioactive polyphenolic compounds naturally
occurring in fruits, vegetables, and beverages of plant origin, have
been hypothesised to account at least partially for such risk
reductions (Pierini et al, 2008). Experimental studies have
supported this hypothesis. For example, freeze-dried berries, which
are high in anthocyanidins, inhibited 24–56% of oesophageal
tumour multiplicity (average number of tumours per oesophagus)
and 8–21% of incidence in rats caused by N-nitrosomethylbenzy-
lamine compared with controls (Stoner et al, 2006). In addition,
Flavopiridol, a synthetic flavone, has been studied in small phase
I and II clinical trials in patients with metastatic gastric cancer but
was an inactive chemopreventive strategy (Schwartz et al, 2001).
However, this clinical trial was undertaken without any epidemio-
logic evidence to support the use of flavonoids. Lignans are another
group of polyphenolic compounds that have anti-inflammatory
and pro-apoptotic effects, antioxidant properties, and promote cell
cycle arrest (Huang et al, 2010).
Recent epidemiological investigations conducted in the United
States (Bobe et al, 2009), Greece (Lagiou et al, 2004), Italy (Rossi
et al, 2007, 2010), Europe (Zamora-Ros et al, 2012; Vermeulen
et al, 2013), Sweden (Ekstrom et al, 2011), China (Sun et al, 2002),
and Mexico (Hernandez-Ramirez et al, 2009) have analysed
associations between flavonoid or lignan intake and oesophageal
or gastric cancer incidence. However, no epidemiologic studies to
date have examined associations between flavonoid intake and
survival among oesophageal or gastric cancer patients. Clarification
of whether total flavonoids, or specific flavonoid classes, influence
the incidence of these tumour subtypes or survival once diagnosed
would provide empirical support for developing potential risk
reduction strategies utilising these compounds.
In this population-based study, we investigated whether intakes
of total flavonoids, including specific flavonoid classes, and lignans
are associated with: (1) oesophageal or gastric cancer incidence and
(2) survival among individuals diagnosed with oesophageal or
gastric cancer. For both aims, we consider associations for all four
cancer types separately.
MATERIALS AND METHODS
To conduct this ancillary study, we built upon the resources from
the USA Multicenter Study, a population-based investigation
conducted in the state of Connecticut (CT, principal investigator
(PI): HA Risch), a 15-county area of New Jersey (NJ, PI: MD
Gammon), and a three-county area of western Washington state
(WA, PI: TL Vaughan), which was initiated as a case-control study
(Gammon et al, 1997) and then continued as a follow-up study to
determine vital status among the cases (Trivers et al, 2005). This
study was approved by all Institutional Review Boards of the
participating institutions.
Study population. The three geographic areas (CT, NJ, and WA)
each had a population-based cancer registry that was used to
identify the cases through rapid reporting methods. Eligible case
participants were English-speaking men and women between the
ages of 30 and 79 years, diagnosed with a first primary invasive
oesophageal or stomach cancer between 1993 and 1995. The parent
study goal was to recruit all individuals newly diagnosed with OEA
and GCA (which were considered the target case participants),
whereas participants with OES or OGA (i.e., comparison cases)
were frequency matched to the expected target case participants
by geographic location and 5-year age group (CT, NJ, and WA),
sex (NJ and WA), and race (white or other, NJ). Final
determination of case participant eligibility and classification was
made by study pathologists (Drs Heidi Rotterdam at Columbia
University for NJ and A Brian West at New York University for CT
and WA) after review of medical records and pathology specimens
(Gammon et al, 1997).
Population-based control participants were frequency matched to
the target case participants by 5-year age group and sex. Control
participants 30–64 years of age were identified using a modified
Waksberg random digit dialing technique (Waksberg, 1978). Control
participants 65–79 years of age were identified by random sampling of
Health Care Financing Administration rosters (now Centers for
Medicare and Medicaid Services) (Gammon et al, 1997).
Study participants included 293 individuals with OEA and 261
with GCA (80.6% of eligible target case participants), 221 with OES
and 368 with OGA (74.1% of eligible comparison case partici-
pants), and 695 population control participants (74.1% of eligible
control participants) (Gammon et al, 1997). The 93.4% of
participants with dietary intake information are the focus of the
current study, and the distribution of the demographic character-
istics of this subsample did not differ substantially from those of all
study participants (Mayne et al, 2001) (Supplementary Table 1).
Males comprised 83.9% of target cases, 72.9% of comparison cases,
and 79.8% of controls; 98.1% of target cases, 83.3% of comparison
cases, and 93.2% of controls were white; and 78.4% of target cases,
66.0% of comparison cases, and 79.2% of controls had more than a
high school education.
Exposure assessment. Information on demographic factors,
tobacco and alcohol use, intake of other beverages (e.g., coffee
and tea), medical history, medication use, and occupational history
was obtained by a structured questionnaire administered face to
face by trained interviewers. Because of the high lethality of these
tumours, proxy interviews (usually with a spouse or other next-of-
kin) were required for 29.6% of target case participants, 32.2%
of comparison case participants, and 3.4% of control participants.
We analysed the data both including and excluding proxy
interviews and the results were consistent (Supplementary
Tables 2 and 3), and therefore we present the analysis including
the proxy data. The average time between cancer diagnosis and
interview for cases was 3.7 months for self-report and 8.5 months
for proxy report. Interviews averaged 130 min. Written informed
consent was obtained from each participant before the interview
(Gammon et al, 1997).
Dietary data were collected by interviewers using a 104-item
food frequency questionnaire (FFQ) modified from one developed
and validated by investigators at the Fred Hutchinson Cancer
Research Center (FHCRC) (Kristal et al, 1997). Participants were
asked to report usual dietary intake for 3–5 years before diagnosis
(case participants) or interview (control participants). Completed
FFQs were not obtained for 33 participants who provided only
abbreviated interviews. Estimated total energy intake of o500 or
44000 kilocalories per day for women and o800 or 45000 kilo-
calories per day for men were considered implausible intake
values, thereby excluding 61 case and 28 control participants
(Willett, 2012). Final numbers of participants included in this
study were 274 with OEA, 248 with GCA, 191 with OES, and
341 with OGA cases, and 662 control participants.
Assessment of dietary flavonoid intake. A study-specific
flavonoid database was created based on values from the
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2011 United States Department of Agriculture (USDA) Database
for the Flavonoid Content of Selected Foods (Bhagwat et al, 2011)
and the 2008 USDA-Iowa State University Database on the
Isoflavone Content of Selected Foods (Bhagwat et al, 2008) and
supplemented with lignan content data (i.e., secoisolariciresinol
and matairesinol) (Thompson et al, 2006). Using FFQ reported
frequencies of dietary intakes, intake of total flavonoids and six
classes of flavonoids (anthocyanidins, flavan-3-ols, flavanones,
flavones, flavonols, and isoflavones) and lignans were estimated
using the study-specific flavonoid database for 81 food and
beverage items that contained measureable amounts of flavonoids
(Supplementary Table 4).
When FFQ items represented groups of foods or beverages, the
individual foods and beverages were weighted based on usual
population consumption. For example, the FFQ item of ‘apples and
pears’ was assigned weights of 0.75 for ‘apples’ and 0.25 for ‘pears’.
Flavonoid intake was calculated by multiplying the weight assigned
to each food in the FFQ item by the flavonoid content of that food,
summing across all foods in the FFQ item, and then multiplying by
the number of times consumed per day. For example, 100 g of
apple contains 1.29 mg and pears contain 12.18 mg of antho-
cyanidins. A serving size of apples or pears was estimated as
145 g. Therefore, if an individual reported consuming one serving
of apples or pears per day, the individual’s daily intake of
anthocyanidins from apples and pears was calculated as 145 g apple
or pear per day [(0.75 apple weight 1.29 mg per 100 g
apples)þ (0.25 pear weight 12.18 mg per 100 g pear)]¼ 5.82 mg
anthocyanidins per day.
Outcome assessment. In follow-up of the Multicenter Study, vital
status and date of death were determined by linking state tumour
registry data with the National Death Index. Overall survival time
(in months) was calculated from the date of diagnosis until death
or last follow-up, with a maximum follow-up of 90 months, ending
in 2000. Median survival time was 9.6 months for the study
participants diagnosed with OEA, 12.8 months for those with
GCA, 10.7 months for OES, and 12.9 months for OGA. At the end
of follow-up, participants who were still alive were considered
censored. The outcome was death from any cause (Trivers et al,
2005).
Statistical analysis. All analyses were conducted using SAS
version 9.2 (SAS Institute, Cary, NC, USA).
Case–control analysis. Polytomous unconditional logistic regres-
sion was used to calculate odds ratios (ORs) and their 95%
confidence intervals (CIs) for the association between flavonoid/
lignan intake and the risk of incidence for the four tumour
types (OEA, GCA, OES, and OGA) in comparison with control
participants. Effect measure modification by cigarette smoking
(evaluated as ever/never and continuous duration), usual adult
body mass index (BMI, evaluated as continuous and as
dichotomised, o25 and X25 kg m 2), and self-reported gastro-
esophageal reflux disease (yes/no) was assessed using likelihood
ratio statistics to compare regression models with and without a
multiplicative term (Rothman et al, 2008). There was no evidence
for effect modification by any of these variables (PX0.05) on the
association between flavonoid intake and oesophageal or gastric
cancer.
Potential confounders for the case–control analysis included
proxy status (proxy, non-proxy), income (evaluated as o$15 000,
$15 000–29 999, $30 000–49 999, $50 000–74 999, or X$75 000 and
o$15 000 or X$15 000), education (evaluated as ohigh school,
high school, technical school/some college, or Xcollege and ohigh
school or Xhigh school), cigarette smoking (evaluated as ever/
never, continuous pack-years, and continuous cigarettes/day),
alcohol consumption (evaluated as ever/never and continuous for
beer, wine, and liquor), and BMI (evaluated as continuous and
categorised, o25, 25–29.9, or X30 kg m 2). If the log OR changed
by X10% because of variable elimination, the variable was
considered a confounder and remained in the model (Rothman
et al, 2008); only cigarette smoking met this criterion. Total energy
intake was included for adjustment as an a priori confounder
(Willett et al, 1997). Thus, all final logistic regression models
include cigarette smoking (ever/never), kilocalories (continuous),
and the frequency matching factors of site (CT, NJ, and WA), age
(continuous), sex (male, female), and race (white, other). Although
we chose to present results adjusted utilising the standard
multivariate approach for ease of interpretation, we also examined
utilising the nutrient density and residual models and results did
not differ (Willett, 2012) (Supplementary Table 5). Ratios of the
ORs were calculated to determine heterogeneity between OEA and
the other cancer subtypes.
Survival analysis. Cox proportional hazard regression analysis
was used to calculate adjusted hazard ratios (HRs) and their
95% CIs for the association between flavonoid/lignan intake and
mortality for each tumour type as distinct outcomes. The
proportional hazards assumption was tested utilising an interaction
with log(time) in models with confounders, and it was not
observed to be violated.
Potential confounders for the survival analysis included the
same covariates listed above in the case–control analysis, as well as
study site (WA, NJ, and CT), age (continuous), sex (male, female),
tumour stage (localised, regional, distant, and unknown), tumour
grade (well/moderate, poor/undifferentiated, and not determined),
and dysphagia (yes, no). Variables remained in the adjusted model
if they were significant predictors of survival (Po0.05) (Rothman
et al, 2008); only stage met this criterion. Total energy intake was
included as an a priori confounder (Willett et al, 1997). Thus, all
final proportional hazard models included tumour stage and
kilocalories (continuous). Stratified Cox proportional hazard
regression analysis, with interaction terms between cancer type
and flavonoids, tumour stage, and total energy intake, was used to
calculate the ratio of the HRs to determine heterogeneity between
EA and the other cancer subtypes.
Examination of linear trend. Flavonoid intake was categorised as
quartiles, based on the distribution of intake among the controls
(logistic regression) or all cases (survival analysis) (Willett, 2012).
To examine trends, we evaluated flavonoid intake with restricted
quadratic splines as well as linear trends in continuous flavonoid
values (mg per day).
Sensitivity analysis. For anthocyanidins, a value of 7.39 mg per
100 g of banana is assigned in the USDA Flavonoid Database
(Bhagwat et al, 2011). However, this value is controversial
(Drossard et al, 2011). Thus, we conducted sensitivity analyses
that excluded this value (Supplementary Tables 6–9). We also
stratified incidence and mortality risk estimates by tumour stage
(Supplementary Tables 10 and 11).
RESULTS
As shown in Table 1, control participants consumed on average
similar amounts of total flavonoids (median¼ 97.09 mg per day) as
case participants (OEA median¼ 96.89; GCA median¼ 104.27;
OES median¼ 108.97; OGA median¼ 101.32 mg per day). Flavan-
3-ols were the largest contributor to total flavonoid intake in this
study population, and control participants consumed less flavan-
3-ols than OEA, GCA, and OGA case participants.
Table 2 lists the major sources of flavonoids and lignans in the
reported food items of the control participants. For total
flavonoids, black tea provided 55.8% (105.11 mg per day) of mean
intake, orange/grapefruit juice 14.2% (26.75 mg per day), and wine
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4.5% (8.46 mg per day). Black tea was a source of flavan-3-ols,
flavonols, and lignans. Orange/grapefruit juice provided flava-
nones, flavonols, isoflavones, and lignans. Wine was a source of
anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, and
lignans.
As shown in Table 3, intake of dietary anthocyanidins, for which
wine, bananas, and fruit juice were the major dietary sources, was
inversely associated with risk of incidence for all tumour types,
although the magnitude and precision of the estimates varied by
tumour type. Comparing the highest with lowest quartile of
anthocyanidin intake, decreased risks were shown for incident
OEA (OR¼ 0.43, 95% CI¼ 0.29–0.66, Ptrend¼ 0.06) and OES
(OR¼ 0.43, 95% CI¼ 0.26–0.70, Ptrend¼ 0.11). More modest
decreased risks were shown for incident GCA (OR¼ 0.71, 95%
CI¼ 0.46–1.10) and OGA (OR¼ 0.70, 95% CI¼ 0.47–1.03), but
the CI included the null value.
For all other flavonoid types, the associations with incident
oesophageal and gastric cancers were less consistent. For example,
as also shown in Table 3, dietary flavanone intake was inversely
associated with incident OEA (OR¼ 0.56, 95% CI¼ 0.37–0.85,
Ptrend¼ 0.003) and OES (OR¼ 0.48, 95% CI¼ 0.29–0.78,
Ptrend¼ 0.002). Dietary flavone and lignan intake were inversely
associated with OES incidence (OR¼ 0.55, 95% CI¼ 0.34–0.89,
Ptrend¼ 0.02; OR¼ 0.38, 95% CI¼ 0.23–0.63, Ptrend¼ 0.0003,
respectively). Lignan intake was more modestly associated with
incident OEA (OR¼ 0.75, 95% CI¼ 0.49–1.13), but the CI
included the null value.
As also shown in Table 3, we observed a modest inverse
association between dietary intake of isoflavones, for which coffee,
chili, and white bread were the major dietary sources, and OES
incidence, but the CI included the null value; in contrast, a positive
association was observed for isoflavones in relation to all other
tumour types. Similarly, we observed a modest positive association
for dietary flavonol intake with GCA incidence, but not other
tumour types. Little or no consistent association was observed
between total flavonoid intake or flavan-3-ols, accounting for
64.6% of total flavonoid intake among controls, and any tumour
types.
As presented in Table 4, anthocyanidin intake was associated with
a decreased risk of mortality among GCA cases (highest vs lowest
quartile HR¼ 0.63, 95% CI¼ 0.42–0.95, Ptrend¼ 0.25) and more
modestly among OEA cases (HR¼ 0.87, 95% CI¼ 0.60–1.26), which
included the null value in the CI. Dietary lignan intake was associated
with decreased mortality for OES cases (HR¼ 0.58, 95% CI¼ 0.37–
0.92, Ptrend¼ 0.07) and more modestly for OEA cases (HR¼ 0.78,
95% CI¼ 0.54–1.14), with the CI including the null value. Flavanone
intake was associated with decreased mortality for OGA cases
(HR¼ 0.66, 95% CI¼ 0.46–0.93, Ptrend¼ 0.18). Flavone intake was
associated with modest decreased mortality for OEA cases
(HR¼ 0.83, 95% CI¼ 0.58–1.19), but the CI included the null. In
addition, total flavonoid or flavonol intake was associated with little
or no decreased risk of mortality for any tumour type.
A sensitivity analysis that excluded the anthocyanidin value for
bananas did not substantially alter our results for oesophageal or
gastric cancer incidence or survival (Supplementary Tables 6–9).
DISCUSSION
This is the first population-based study to examine associations
between dietary flavonoid intake and survival among oesophageal
and gastric cancer cases. In our analysis, the highest intake quartile
of anthocyanidins was associated with a possible 37% and more
modest 13% decreased risk of mortality for GCA and OEA cases,
respectively. Lignan intake was associated with a possible 42% and
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cases, respectively. Flavanones was associated with a possible
34% decreased risk of mortality for OGA cases. We also found
flavones associated with a possible 17% decreased risk of mortality
for OEA cases. Although our survival results are intriguing, there
are several aspects regarding our study approach (as discussed
below) that should be kept in mind when interpreting our study
findings.
In addition, we observed possible 25–30% risk reduction for the
associations between anthocyanidins and GCA and OGA incidence
and lignans and OGA incidence. We observed B30–60% risk
reductions for the associations between anthocyanidins and
flavanones and OEA incidence; similar risk reductions were noted
for the associations between the highest intake quartiles of
anthocyanidins, flavanones, flavones, isoflavones, and lignans in
relation to OES. As these four cancer types have differing risk
factors (Hongo et al, 2009; de Martel et al, 2013), it is not
surprising that certain flavonoids differentially influence the risk of
certain subtypes of oesophageal or gastric cancer.
Our findings are consistent with a previous epidemiologic study
that reported an inverse association between anthocyanidin intake
and OEA incidence (Bobe et al, 2009). In addition, our findings
regarding anthocyanidin intake are consistent with the parent
(Gammon et al, 1997) and consortial studies (Freedman et al,
2011) showing a risk reduction for moderate wine intake, the main
source of anthocyanidins in this study. Our results are also
consistent with previous population studies regarding flavanone
and isoflavone intake in relation to OES incidence (Rossi et al,
2007; Bobe et al, 2009). Previous studies, but not our study
reported here, have also noted inverse associations between:
flavonols and OES incidence (Rossi et al, 2007); flavonols
(Lagiou et al, 2004; Rossi et al, 2010), flavanones (Lagiou et al,
2004), flavones (Lagiou et al, 2004), and lignans (secoisolaricir-
esinol; Hernandez-Ramirez et al, 2009) and gastric adenocarci-
noma (i.e., cardia and noncardia) incidence; and flavonols
(quercetin) and GCA incidence (Ekstrom et al, 2011). Observed
differences between these previous studies and our own
could partially be because of considering gastric adenocarcinoma
as a combined entity and not according to anatomic subsite,
examining single flavonoids and not classes of flavonoids,
differences in study populations and dietary patterns across
studies, or chance.
In this study, notable risk reductions were observed for the
associations between anthocyanidins and oesophageal cancer
incidence, regardless of histologic subtype. However, in animal
studies, results for anthocyanidins as chemopreventive agents are
not consistent across histologic subtypes (i.e., squamous cell
carcinoma vs adenocarcinoma). Multiple experimental studies have
shown that anthocyanidin-rich black raspberries have chemopre-
ventive properties in N-nitrosomethylbenzylamine-induced
tumours in rats (OES rodent model) (Stoner et al, 2006). In a
study of oesophagoduodenal anastomosis, a rodent model for
reflux-induced OEA, freeze-dried black raspberries were not
effective in chemoprevention of OEA (Aiyer et al, 2011). However,
interim clinical trial results for Barrett’s oesophagus, a potential
precursor of OEA, found reduced markers of oxidative stress in
Barrett’s oesophagus patients consuming anthocyanidin-rich
freeze-dried black raspberries (Kresty et al, 2006).
A previous study, based on data from the same parent study as
our own, found a modest inverse association between fruit and
vegetable intake and incidence of both histologic subtypes of
oesophageal cancer (Navarro Silvera et al, 2008). As flavonoids are
concentrated in fruits and vegetables (D’Archivio et al, 2007), the
association between flavonoids and oesophageal or gastric cancer
incidence may reflect diets with greater consumption of such foods
or a healthy lifestyle in general. The parent study assessed many
lifestyle factors, including cigarette smoking, alcohol intake, and
BMI, individually (Gammon et al, 1997) and through the use of
pattern analyses (Navarro Silvera et al, 2008). Cigarette smoking
was the only covariate among these that influenced our findings
and was adjusted for in the final models. Thus, lifestyle seems
unlikely to account for our results.
When estimating flavonoid content in food, particularly fruits
and vegetables, potential sources of error include plant varieties,
degree of ripeness, storage conditions, distance transported to
market, environmental factors affecting plant growth, horticultural
practices, industrial processing, and cooking methods that may
vary over time and by geographic region (D’Archivio et al, 2007).
Therefore, the foods utilised to create the nutrient database
Table 2. Major sources of flavonoids and lignans among a population-based sample of control participants without oesophageal




Representative flavonoids Main FFQ line item sources (%)
Total flavonoids Black tea (55.8), orange/grapefruit juice (14.2), wine (4.5)
Anthocyanidins Cyanidin, Delphinidin, Malvidin,
Pelargonidin, Peonidin, Petunidin
Wine (29.1), banana (13.7), fruit juice (10.6), other fruit (fruit cocktail, grapes, pineapple,
blueberries, applesauce) (9.0), apples (7.5), pies (6.0), bean soup (5.9)
Flavan-3-ols (þ )-Catechin, (þ )-Catechin-3-gallate,
( )-Epicatechin, ( )-Epicatechin-3-
gallate, ( )-Epigallocatechin,
( )-Epigallocatechin- 3-gallate,





Black tea (83.7), beer (3.2), green tea (3.1), wine (2.0), apples (1.9),
bananas (1.4)
Flavanones Eriodictyol, Hesperetin, Naringenin Orange/grapefruit juice (75.4), oranges (21.5), wine (1.8)
Flavones Apigenin, Luteolin Pizza (27.5), Wine (13.0), Celery (8.3), vegetable soup (7.8), mixed salad (7.8), cream soups
(7.0), chicken noodle soup (5.4)
Flavonols Isorhamnetin, Kaempferol, Myricetin,
Quercetin
Black tea (22.9), onions (10.5), beer (9.2), apples (8.1), wine (5.9), mixed salad (5.9)
Isoflavones Daidzein, Genistein, Glycitein Coffee (36.8), chili (17.4), white bread (10.8), cake (8.4), fried chicken (5.1), sausage (4.5)
Lignans Matairesinol, Secoisolariciresinol Coffee (34.8), orange/grapefruit juice (13.4), wine (10.3), black tea (5.0), onions (3.5)
Abbreviation: FFQ, food frequency questionnaire.
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estimates may differ from the actual food sources reportedly
consumed by this study population (Thompson et al, 2006;
Bhagwat et al, 2008, 2011). To estimate the potential impact of
such influences, the USDA Food Composition and Nutrient Data
Laboratories sampled over 60 fruits, vegetables, and nuts from four
USA regions at two times of the year and estimated the flavonoid
content. Values reported in the USDA databases were similar to
average flavonoid content determined in this study, although high
variability of flavonoid content was seen within and between foods
(Harnly et al, 2006). In addition, the FFQ line item for wine did not
distinguish between red and white that have different flavonoid
concentrations (Bhagwat et al, 2011). In our study reported here,
weights of 50% for red and 50% for white were assigned. However,
individuals often preferentially drink red or white wine, and thus
individual estimates of flavonoid types for which wine is a source
may be misclassified.
Bioavailability of flavonoid compounds is another potential
source of error when estimating the amount of flavonoid intake
necessary to reduce risk of oesophageal or gastric cancer. However,
little is known about flavonoid absorption in the gastrointestinal
tract, metabolism of flavonoids varies by individual, and the degree
to which flavonoids might have direct effects on epithelial surfaces
Table 3. Adjusteda odds ratios (ORs) and 95% confidence intervals (CIs) for associations between flavonoid and lignan intakes
































0–63.81 165 83 1.00 59 1.00 48 1.00 80 1.00
63.82–97.90 166 54 0.62 (0.41, 0.93)b,c 60 1.00 (0.65, 1.54) 35 0.64 (0.38, 1.07)b 84 1.01 (0.69, 1.49)c
97.91–217.35 165 57 0.64 (0.42, 0.97) 54 0.90 (0.58, 1.41) 61 1.11 (0.69, 1.77) 78 0.92 (0.62, 1.37)
X217.36 166 80 0.92 (0.63, 1.37) 75 1.32 (0.87, 2.00) 47 0.87 (0.53, 1.41) 99 1.08 (0.73, 1.58)
P for trendd 0.61 0.07 0.42 0.50
Anthocyanidins
0–7.21 166 98 1.00 67 1.00 67 1.00 92 1.00
7.22–11.53 165 69 0.65 (0.45, 0.96) 67 0.98 (0.65, 1.47) 51 0.68 (0.43, 1.06) 89 0.91 (0.63, 1.32)
11.54–18.47 165 59 0.54 (0.36, 0.81)c,e 63 0.91 (0.60, 1.38)e 37 0.44 (0.27, 0.72) 91 0.89 (0.61, 1.29)c
X18.48 166 48 0.43 (0.29, 0.66) 51 0.71 (0.46, 1.10) 36 0.43 (0.26, 0.70) 69 0.70 (0.47, 1.03)
P for trendd 0.06c,e 0.91e 0.11 0.10c
Flavan-3-ols
0–10.29 165 75 1.00 59 1.00 45 1.00 71 1.00
10.30–22.00 166 61 0.72 (0.48, 1.09)c 50 0.77 (0.50, 1.20) 37 0.78 (0.47, 1.30) 101 1.45 (0.99, 2.14)c
22.01–130.69 165 56 0.65 (0.43, 1.00) 69 1.05 (0.69, 1.61) 62 1.24 (0.77, 2.00) 68 0.98 (0.65, 1.48)
X130.70 166 82 1.02 (0.69, 1.51) 70 1.17 (0.77, 1.78) 47 0.98 (0.60, 1.59) 101 1.30 (0.88, 1.92)
P for trendd 0.32 0.07 0.68 0.36
Flavanones
0–11.57 166 91 1.00 62 1.00 61 1.00 89 1.00
11.58–34.95 165 61 0.67 (0.45, 1.00) 54 0.86 (0.56, 1.33) 45 0.70 (0.44, 1.11) 80 0.92 (0.63, 1.35)
34.96–49.52 165 69 0.75 (0.50, 1.10) 59 1.01 (0.66, 1.55) 49 0.69 (0.43, 1.10) 83 0.86 (0.59, 1.27)
X49.53 166 53 0.56 (0.37, 0.85)e 73 1.23 (0.81, 1.87)e 36 0.48 (0.29, 0.78) 89 0.88 (0.60, 1.28)
P for trendd 0.003e 0.82e 0.002 0.36
Flavones
0–1.29 165 82 1.00 60 1.00 71 1.00 95 1.00
1.30–1.90 166 58 0.67 (0.45, 1.00) 55 0.87 (0.57, 1.34) 51 0.70 (0.45, 1.09) 87 0.92 (0.64, 1.34)
1.91–2.62 166 59 0.68 (0.45, 1.02)b 62 0.98 (0.64, 1.50) 28 0.34 (0.20, 0.57)b 72 0.77 (0.52, 1.13)
X2.63 165 75 0.84 (0.56, 1.25) 71 1.09 (0.71, 1.67) 41 0.55 (0.34, 0.89) 87 1.01 (0.69, 1.50)
P for trendd 0.81b 0.15 0.02b 0.98
Flavonols
0–8.31 166 86 1.00 52 1.00 56 1.00 82 1.00
8.32–12.16 165 49 0.56 (0.37, 0.85)e,f 64 1.24 (0.81, 1.91)e 33 0.59 (0.36, 0.98) 94 1.16 (0.80, 1.69)c
12.17–17.81 166 61 0.67 (0.45, 1.00) 53 1.01 (0.65, 1.57) 39 0.70 (0.43, 1.14) 79 0.96 (0.65, 1.41)
X17.82 165 78 0.80 (0.54, 1.18)e 79 1.42 (0.93, 2.17)e 63 0.97 (0.62, 1.53) 86 0.98 (0.67, 1.46)
P for trendd 0.71 0.10 0.70 0.92
Isoflavones
0–0.27 165 47 1.00 36 1.00 34 1.00 65 1.00
0.28–0.41 166 51 0.98 (0.61, 1.55) 64 1.55 (0.97, 2.49) 50 1.12 (0.67, 1.89) 90 1.45 (0.97, 2.17)
0.42–0.59 166 83 1.51 (0.97, 2.37) 73 1.62 (1.00, 2.63) 59 1.18 (0.69, 2.00) 97 1.68 (1.10, 2.56)
X0.60 165 93 1.65 (1.02, 2.65)b 75 1.56 (0.93, 2.60) 48 0.72 (0.40, 1.29)b 89 1.50 (0.96, 2.37)
P for trendd 0.07b 0.17 0.11b 0.37
Lignans
0–0.045 165 70 1.00 50 1.00 67 1.00 87 1.00
0.046–0.063 166 75 0.91 (0.61, 1.36) 61 1.06 (0.69, 1.65) 47 0.64 (0.40, 1.01) 92 1.09 (0.75, 1.59)
0.064–0.082 165 57 0.65 (0.42, 0.99)c,e 70 1.17 (0.76, 1.81)e 42 0.50 (0.31, 0.82) 98 1.11 (0.76, 1.63)c
X0.083 166 72 0.75 (0.49, 1.13)b 67 1.01 (0.65, 1.58) 35 0.38 (0.23, 0.63)b 64 0.73 (0.48, 1.11)
P for trendd 0.26b 0.63 0.0003b 0.13
aAdjusted for age (continuous), sex, race (white, other), geographic centre (Connecticut, New Jersey, Washington), cigarette smoking (ever/never), and dietary energy intake (kilocalories,
continuous).
bP-value o0.05 for the ratio of the odds ratios comparing OEA vs OES.
cP-value o0.05 for the ratio of the odds ratios comparing OEA vs OGA.
dP-value for trend for continuous variable.
eP-value o0.05 for the ratio of the odds ratios comparing OEA vs GCA.
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as they traverse the oesophagus and stomach is unclear (Bravo,
1998). In addition, absorption profiles of flavonoids vary, with
maximum concentrations reached between 0.5 and 9 h after dietary
intake (Spencer et al, 2008). Thus, serum flavonoid biomarkers may
not be highly correlated with usual adult dietary intake. Although
such variation in estimating representative dietary flavonoid intakes
and bioavailability may be a study limitation, this issue would apply
to greater or lesser degrees to all studies reliant on nutritional
databases to estimate dietary intake (Willett, 2012).
Patients with gastroesophageal reflux disease or Barrett’s
oesophagus are recommended to omit foods that are mechanically
or chemically irritating, including some flavonoid-rich foods
Table 4. Adjusteda hazard ratios (HRs) and 95% confidence intervals (CIs) for flavonoid and lignan intakes and overall mortality in






























0–62.35 83 1.00 57 1.00 47 1.00 76 1.00
62.36–103.39 60 1.37 (0.95, 1.98) 66 1.05 (0.71, 1.54) 42 1.26 (0.81, 1.97) 95 1.01 (0.71, 1.42)
103.40–253.24 65 1.39 (0.97, 1.98)b,c 60 0.79 (0.54, 1.17)b 61 0.92 (0.60, 1.40) 77 0.72 (0.50, 1.05)c
X253.25 66 0.98 (0.68, 1.41) 65 0.88 (0.59, 1.32) 41 0.91 (0.58, 1.44) 90 0.99 (0.70, 1.39)
P for trendd 0.11 0.80 0.11 0.90
Anthocyanidins
0–6.23 83 1.00 52 1.00 57 1.00 70 1.00
6.24–10.11 61 0.93 (0.65, 1.35) 64 0.76 (0.51, 1.12) 52 0.77 (0.50, 1.18) 86 1.27 (0.89, 1.82)
10.12–16.23 67 0.88 (0.62, 1.26) 66 0.80 (0.54, 1.18) 41 1.46 (0.94, 2.26) 89 1.22 (0.84, 1.76)
X16.24 63 0.87 (0.60, 1.26) 66 0.63 (0.42, 0.95) 41 1.01 (0.66, 1.56) 93 1.14 (0.80, 1.63)
P for trendd 0.14 0.25 0.94 0.55
Flavan-3-ols
0–10.90 80 1.00 61 1.00 47 1.00 75 1.00
10.91–26.67 62 0.92 (0.64, 1.32) 53 0.69 (0.46, 1.04) 46 1.68 (1.08, 2.62) 102 1.33 (0.94, 1.87)
26.68–210.51 66 1.20 (0.84, 1.72)e 71 0.78 (0.54, 1.13) 56 0.97 (0.63, 1.50)e 70 0.96 (0.66, 1.39)
X210.52 66 0.93 (0.65, 1.33) 63 0.71 (0.48, 1.05) 42 1.09 (0.69, 1.74) 91 1.22 (0.87, 1.73)
P for trendd 0.11 0.94 0.10 0.80
Flavanones
0–8.63 81 1.00 55 1.00 50 1.00 77 1.00
8.64–32.94 66 0.96 (0.67, 1.38) 60 1.12 (0.75, 1.69) 54 0.95 (0.61, 1.47) 83 0.70 (0.49, 1.00)
34.95–49.00 71 1.40 (0.99, 1.98)c 57 1.24 (0.83, 1.86) 48 1.05 (0.67, 1.63) 87 0.74 (0.52, 1.05)c
X49.01 56 1.15 (0.79, 1.68)c 76 0.90 (0.61, 1.33) 39 1.24 (0.76, 2.03) 91 0.66 (0.46, 0.93)c
P for trendd 0.05c 0.50 0.80 0.18c
Flavones
0–1.20 79 1.00 46 1.00 64 1.00 74 1.00
1.21–1.81 52 0.97 (0.66, 1.41) 63 1.03 (0.68, 1.56) 48 1.23 (0.82, 1.84) 100 0.88 (0.63, 1.24)
1.82–2.64 73 0.89 (0.63, 1.26) 70 0.95 (0.63, 1.44) 39 0.88 (0.56, 1.38) 80 0.88 (0.61, 1.26)
X2.65 70 0.83 (0.58, 1.19) 69 0.86 (0.56, 1.31) 40 1.00 (0.64, 1.54) 84 0.97 (0.67, 1.39)
P for trendd 0.04 0.54 0.17 0.62
Flavonols
0–8.16 79 1.00 50 1.00 55 1.00 79 1.00
8.17–12.30 60 1.30 (0.89, 1.89) 68 1.25 (0.83, 1.87) 36 1.14 (0.70, 1.83) 98 1.12 (0.80, 1.57)
12.31–19.34 72 1.01 (0.71, 1.43) 63 1.11 (0.74, 1.68) 45 0.78 (0.50, 1.20) 84 1.09 (0.78, 1.54)
X19.35 63 0.94 (0.65, 1.37) 67 0.93 (0.61, 1.40) 55 0.93 (0.61, 1.40) 77 0.97 (0.68, 1.38)
P for trendd 0.05 0.35 0.69 0.71
Isoflavones
0–0.31 65 1.00 59 1.00 48 1.00 89 1.00
0.32–0.46 56 1.00 (0.68, 1.47) 57 1.26 (0.84, 1.87) 60 1.03 (0.68, 1.58) 90 1.29 (0.92, 1.82)
0.47–0.62 73 0.70 (0.48, 1.03) 68 0.94 (0.62, 1.44) 42 1.14 (0.71, 1.81) 81 0.86 (0.60, 1.25)
X0.63 80 0.75 (0.49, 1.13) 64 1.01 (0.65, 1.57) 41 0.97 (0.60, 1.58) 78 0.92 (0.62, 1.37)
P for trendd 0.65 0.77 0.60 0.88
Lignans
0–0.044 68 1.00 50 1.00 62 1.00 83 1.00
0.045–0.060 72 0.85 (0.60, 1.23) 55 1.45 (0.95, 2.22) 50 0.73 (0.47, 1.13) 85 1.22 (0.86, 1.73)
0.061–0.079 57 0.98 (0.67, 1.45) 66 1.05 (0.70, 1.59) 41 0.61 (0.39, 0.96) 99 1.08 (0.77, 1.51)
X0.080 77 0.78 (0.54, 1.14) 77 0.97 (0.65, 1.46) 38 0.58 (0.37, 0.92) 71 1.05 (0.72, 1.53)
P for trendd 0.28 0.43 0.07 0.55
aAdjusted for stage (localised, regional, distant, unknown) and dietary energy intake (kilocalories, continuous).
bP-value o0.05 for the ratio of the hazard ratios comparing OEA vs GCA.
cP-value o0.05 for the ratio of the hazard ratios comparing OEA vs OGA.
dP-value for trend for continuous variable.
eP-value o0.05 for the ratio of the hazard ratios comparing OEA vs OES.
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(e.g., coffee, tea, alcohol, citrus, tomatoes, chocolate, peppers, and
onions) (Ko et al, 2008). Although the FFQ assessed diet before
diagnosis, OEA patients may already have symptoms before
diagnosis, causing their usual diet to change or, perhaps, reporting
of past diet could be influenced by current dietary habits. However,
the foods that are irritating vary by individual (Brown, 2008); thus,
we are unable to estimate how such potential changes in diet would
have affected flavonoid intake values. In addition, a dietary study
showed that intakes of fruits, vegetables, and alcohol did not differ
by symptomatic gastroesophageal reflux disease status (El-Serag
et al, 2005). Although it is unknown whether gastroesophageal
reflux disease or Barrett’s oesophagus are necessary precursors of
OEA (Shaheen and Ransohoff, 2002), it is still possible that
associations observed in case–control studies between flavonoid
intake and risk of OEA are due to reverse causation. However, in
examining the comparison case group of OES, we see similar
associations, with the exception of isoflavones. Thus, it seems
unlikely that our observed associations are completely because of
reverse causation.
Although our observed association with oesophageal and gastric
cancers could possibly reflect a true association with select
flavonoid classes, or perhaps a healthy prediagnostic behaviour
lifestyle in general, there are additional measurement issues to
consider during the interpretation of our findings. For example,
FFQ responses for the 3–5 years before diagnosis are assumed to
reflect usual adult diet, both pre- and post-diagnosis. Whether such
time period reflects intakes during the time relevant to oesophageal
and gastric cancer development is unknown. However, because all
existing oesophageal and gastric cancer studies have relied on FFQs
(Lunet et al, 2007; Li et al, 2014), one would need to conduct a
cohort study and employ multiple alternative dietary assessment
methods over time to overcome limitations of existing studies.
Such an alternative study design would be very inefficient, because
the lifetime risk of oesophageal or gastric cancer in the general
United States population is o1% (Howlader et al). Similarly for
the survival analyses, potential changes in dietary intake after
diagnosis may be a relevant exposure but we were not able to assess
this from available data.
Our study FFQ did not assess dietary supplement use of flavo-
noids. However, it is unlikely that use of flavonoid-rich supplements
was widespread during this study time period, as flavonoid
supplements were not patented in the United States until after
completion of participant interviews in our parent study (U.S. Patent
Office). In addition, we were unable to assess post-diagnosis
medications or first course of treatment that may confound the
survival analyses. Finally, the majority of participants were Caucasian
males with low socioeconomic status. The overwhelming majority of
individuals who develop oesophageal and gastric cancer are
Caucasian males (Falk, 2009). Thus, the results are still largely
generalisable to those at highest risk of developing these deadly
cancers.
Multiple comparisons need to be considered when discussing the
study results, as there were 64 comparisons within the main
analyses, given we considered 8 exposures and 8 outcomes. Thus,
there is a possibility that some statistically significant results arose
because of chance. Adjusting for multiple comparisons would reduce
the likelihood of detecting a false positive association, but would
reduce power for detecting a true association if one exists. Instead,
we chose to focus on associations based on biologic plausibility and
consistency with published results (Rothman, 1990; Willett, 2012);
we also gave more credence to results that were consistent across the
continuum of cancer development. For example, in this study, we
noted inverse associations for both incidence and survival for OEA
in relation to anthocyanidin intake.
In summary, our population-based findings suggest that dietary
intake of some types of flavonoids, particularly anthocyanidins,
may lower the risk of oesophageal and gastric cancer incidence and
may potentially enhance survival. This is the first epidemiologic
study to examine the association of flavonoids and lignans with
survival among oesophageal and gastric cancer cases, and one of
few studies to examine these compounds in associations with the
risk of incident oesophageal and gastric cancer by tumour type.
Our findings here on anthocyanidins are consistent for incidence
and survival of OEA and GCA, suggesting that these compounds
could perhaps potentially be used in an effort to reduce
mortality because of these fatal cancers. However, further research
is needed before definite conclusions can be made about the
chemopreventive role of dietary flavonoids and lignans on
oesophageal and gastric cancer incidence and survival.
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